SGLT-2 Inhibitors Tied to Lower Risk for Autoimmune Rheumatic Diseases in Adults With T2D
Research shows that SGLT-2 inhibitors are associated with a reduced risk for autoimmune rheumatic diseases compared to sulfonylureas in adults with type 2 diabetes.
- The study, conducted by Bin Hong and colleagues from Sungkyunkwan University, involved a retrospective cohort of 2,032,157 adults with type 2 diabetes from a South Korean healthcare database.
- After propensity score weighting, the analysis included 1,030,088 SGLT-2 inhibitor initiators and 1,002,069 sulfonylurea initiators.
- The weighted incidence rate was 51.90 and 58.41 per 100,000 person-years for SGLT-2 inhibitors and sulfonylureas, respectively.
No direct quote available in the given text.
Author's summary: SGLT-2 inhibitors reduce risk.
More News
- Guadeloupean artist Kelly Sinnapah Mary wins French art prize at Art Basel Miami Beach
- Spurs' Luke Kornet out Friday
- When does 2026 F1 season start?
- How to watch Islanders vs. Lightning: TV channel and streaming options for December 6
- Game Preview: Islanders vs Lightning
- How former Gonzaga stars perform in NBA
- Pelicans' Questionable Offseason Trade Looks Better After Saddiq Bey's Rise
- Islanders vs. Lightning (Dec 6, 2025) Pregame
- Lightning vs. Islanders Prediction, Odds, Picks - Dec. 6
- Jay Kelly cast guide: All on which characters George Clooney, Adam Sandler and Laura Dern play in the film